Olanzapine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Olanzapine: From Antipsychotic Use to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Olanzapine is an antipsychotic that is currently marketed in South Africa. The TxGNN model predicts it may be effective for benign paroxysmal torticollis of infancy, but no clinical trials and no publications currently support this prediction. It is a model-only signal, so the recommendation is to hold.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Benign paroxysmal torticollis of infancy |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the Evidence Pack. Olanzapine is generally described as a dopamine D2 and serotonin 5-HT2A antagonist, and this is the only mechanistic basis available for this report.
This prediction is hard to justify mechanistically. Benign paroxysmal torticollis of infancy is generally considered a migraine equivalent, often linked to CACNA1A variants. No established mechanistic bridge connects D2/5-HT2A antagonism to that pathway.
The clinical picture argues against use. The patients are infants, and the condition is self-limiting. Olanzapine’s metabolic and sedative risks make a favourable benefit-risk balance implausible without direct evidence. The high TxGNN score (99.54%) should be read as a statistical association in the knowledge graph, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 44/2.6.5/1019 | Olawin Film Coated 2,5 Mg | Film-coated tablet |
| Reg. No. 42/2.6.5/0814 | Redilanz 2,5 | Tablet |
| Reg. No. 45/2.6.5/0166 | Mylan olanzapine | Tablet |
| Reg. No. 44/2.6.5/0447 | Zylena | Tablet |
Approved indication text was not included in the registration data supplied. All registrations are oral solid dosage forms.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no trials or literature. The condition has no plausible mechanistic link to olanzapine, and the patients are infants with a self-limiting course. The metabolic and sedative risks of olanzapine would very likely outweigh any benefit.
To proceed, the following is needed:
- Any direct clinical or preclinical evidence for olanzapine in this condition
- Mechanism of action data (MOA)
- SAHPRA package insert warnings and contraindications, which are needed before any safety screening
- Paediatric safety data for olanzapine
Note on other predictions: Among the other predicted indications, agoraphobia (score 99.47%) has more support. It is at evidence level L3, with one 12-week open-label augmentation trial in treatment-resistant panic disorder (PMID 16415705), two case reports, and two systematic reviews on treatment-resistant anxiety. It is best treated as a research question, not a treatment recommendation. No randomised controlled evidence or registered trials exist, and the conclusions of the systematic reviews on olanzapine have not been verified. Dysthymic disorder (score 99.28%) has no supporting evidence and is also on Hold.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.